Increased cardiovascular risk in HIV infection: Drugs, virus and immunity

AIDS

Volumn 22, Issue 13, 2008, Pages 1625-1627

  Murphy, Robert ^a,b   Costagliola, Dominique ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AGE; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; DISEASE MARKER; DRUG SAFETY; EDITORIAL; FOLLOW UP; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MENOPAUSE; PRIORITY JOURNAL; RACE; SMOKING; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; MALE; NOTE; RISK; VIROLOGY;

ANTI-HIV AGENTS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; RISK;

EID: 52249124129     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328306a6db     Document Type: Editorial

References (13)

1. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D, and the Clinical Epidemiology Group from the French Hospital Database. Increased riskof myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17:2479-2486.
2. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348:702-710.
3. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
4. Holmberg SD, Moorman AC, Williamson JM, Weber R, Monforte A, El-Sadar W, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360:1747-1748.
5. D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration. Lancet 2008. [Accessed April 1 2008] doi:10.1016/S01040-6736(08)60423-7.
6. Sanz E. Abacavir - myocardial infarction. WHO Signal. May 4-6, 2005; http://www.who-umc.org/graphics/15962.pdf. [Accessed 10 April 2008].
7. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-2512.
8. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4R count-guided interruption of antire-troviral treatment. N Engl J Med 2006; 355:2283-2296.
9. Currier JS, Kendall MA, Zackin R, et al. Carotid intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005; 10:927-933.
10. Mangili A, Gerrior J, Tang AM, et al. Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary artery calcium score. Clin Infect Dis 2006; 43:1482-1489.
11. th IAS Conference on HIV Pathogenesis, Treatment and Prevention incorporating the ASHM Conference. 22-25 July 2007. Sydney, Australia. (abstract WEAB302) p. 177.
12. Kingsley LA, Cuervo-Rojas J, Munoz A, et al. Subclinical atherosclerosis, HIV infection and antiretroviral therapy: results from the Multicenter AIDS Cohort Study. AIDS 2008.
13. Kaplan R, Kingsley L, Gange S, et al. Low CD4RT cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008.